Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

TAVALISSE (fostamatinib disodium hexahydrate) for the Treatment of Chronic Immune Thrombocytopenia

Drug Name

TAVALISSE™ (fostamatinib disodium hexahydrate)

Developer

Rigel Pharmaceuticals

Current Indication

Chronic immune thrombocytopenia (ITP)

Market Sector

Haematology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top